Biogen (BIIB) Share-based Compensation (2009 - 2026)

Biogen's Share-based Compensation history runs 18 years deep, the most recent figure standing at $84.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 3.7% year-over-year to $84.0 million; the TTM figure through Mar 2026 stood at $293.8 million (down 1.87% YoY), while the FY2025 annual figure was $290.8 million, changed 0.14% from the prior year.
• Share-based Compensation was $84.0 million for Q1 2026 at Biogen, up from $59.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $84.0 million in Q1 2026 to a low of $54.9 million in Q4 2023.
• Historically, Share-based Compensation has averaged $69.7 million across 5 years, with a median of $71.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 36.79% in 2024, then fell 20.64% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $67.2 million in 2022, then decreased by 18.3% to $54.9 million in 2023, then surged by 36.79% to $75.1 million in 2024, then declined by 20.64% to $59.6 million in 2025, then surged by 40.94% to $84.0 million in 2026.
• The last three Share-based Compensation figures came in at $84.0 million (Q1 2026), $59.6 million (Q4 2025), and $75.3 million (Q3 2025), per Business Quant data.